Alopécia androgenética

Starace M, Orlando G, Alessandrini A, et al. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020 Feb;21(1):69-84. Resumo

European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].Texto completo

Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11. Resumo

Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74. Resumo

Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. Resumo

Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004 Apr;50(4):541-53. Resumo

1. Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65. Resumo

2. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977 Sep;97(3):247-54. Resumo

3. Stough D, Stenn K, Haber R, et al. Psychological effects, pathophysiology, and management of androgenic alopecia in men. Mayo Clin Proc. 2005 Oct;80(10):1316-22. Resumo

4. Gan DC, Sinclair RD. Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005 Dec;10(3):184-9.Texto completo  Resumo

5. Rhodes T, Girman CJ, Savin RC, et al. Prevalence of male pattern hair loss in 18-49 year old men. Dermatol Surg. 1998 Dec;24(12):1330-2. Resumo

6. Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metabol Clin N Am. 2007 Jun;36(2):379-98. Resumo

7. Starace M, Orlando G, Alessandrini A, et al. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020 Feb;21(1):69-84. Resumo

8. Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988 May;18(5 Pt 1):1073-7. Resumo

9. Birch MP, Lalla SC, Messenger AG. Female pattern hair loss. Clin Exp. Dermatol. 2002 Jul;27(5):383-88. Resumo

10. Küster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol. 1984 Nov;11(5 Pt 1):921-6. Resumo

11. European Dermatology Forum. S3 - European Dermatology Forum guideline for the treatment of androgenetic alopecia in women and in men. 2017 [internet publication].Texto completo

12. Bergfeld W. Androgenetic alopecia: an autosomal dominant disorder. Am J Med. 1995 Jan 16;98(1A):95S-98S. Resumo

13. Fabbrocini G, Cantelli M, Masarà A, et al. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018 Dec;4(4):203-11.Texto completo  Resumo

14. Trüeb RM. Molecular mechanism of androgenetic alopecia. Exp Gerontol. 2002 Aug-Sep;37(8-9):981-90. Resumo

15. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005 Feb;52(2):301-11. Resumo

16. Itami S, Kurata S, Takayasu S. Androgen induction of follicular epithelial cell growth is mediated via insulin-like growth factor I from dermal papilla cells. Biochem Biophys Res Commun. 1995 Jul 26;212(3):988-94. Resumo

17. Harris G, Azzolina B, Baginsky W, et al. Identification and selective inhibition of an isoenzyme of steroid 5 alpha -reductase in human scalp. Proc Natl Acad Sci. 1992 Nov 15;89(22):10787-91.Texto completo  Resumo

18. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002 Nov;119(5):992-1007.Texto completo  Resumo

19. Jeong KH, Jung JH, Kim JE, et al. Prostaglandin D2-Mediated DP2 and AKT Signal Regulate the Activation of Androgen Receptors in Human Dermal Papilla Cells. Int J Mol Sci. 2018 Feb 12;19(2):556.Texto completo  Resumo

20. González-González JG, Mancillas-Adame LG, Fernández-Reyes M, et al. Androgenetic alopecia and insulin resistance in young men. Clin Endocrinol (Oxf). 2009 Oct;71(4):494-9. Resumo

21. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011 Jan-Feb;21(1):79-82. Resumo

22. Nabaie L, Kavand S, Robati RM, et al. Androgenic alopecia and insulin resistance: are they really related? Clin Exp Dermatol. 2009 Aug;34(6):694-7. Resumo

23. Matilainen V, Laakso M, Hirsso P, et al. Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study. J Cardiovasc Risk. 2003 Jun;10(3):227-31. Resumo

24. Kartal D, Borlu M, Çınar SL, et al. The association of androgenetic alopecia and insulin resistance is independent of hyperandrogenemia: a case-control study. Australas J Dermatol. 2016 Aug;57(3):e88-92. Resumo

25. Giles GG, Severi G, Sinclair R, et al. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):549-53. Resumo

26. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, et al. Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol. 2010 Sep;63(3):420-9. Resumo

27. Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003 Mar-Apr;13(2):150-60. Resumo

28. Springer K, Brown M, Stulberg DL. Common hair loss disorders. Am Fam Physician. 2003 Jul 1;68(1):93-102. Resumo

29. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med. 2007 Oct 18;357(16):1620-30. Resumo

30. Gupta AK, Venkataraman M, Talukder M, et al. Relative efficacy of minoxidil and the 5-α reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022 Mar 1;158(3):266-74.Texto completo  Resumo

31. Olsen EA, Whiting D, Bergfeld W, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007 Nov;57(5):767-74. Resumo

32. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017 Jul;77(1):136-41.e5. Resumo

33. Buhl AE, Waldon, DJ, Conrad SJ, et al. Potassium channel conductance: a mechanism affecting hair growth both in vitro and in vivo. J Invest Dermatol. 1992 Mar;98(3):315-9. Resumo

34. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia after application of 5% and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol. 1999 Nov;41(5 Pt 1):717-21. Resumo

35. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002 Sep;47(3):377-85. Resumo

36. Tsuboi R, Arano O, Nishikawa T, et al. Randomized clinical trial comparing 5% and 1% topical minoxidil for the treatment of androgenetic alopecia in Japanese men. J Dermatol. 2009 Aug;36(8):437-46. Resumo

37. Kanti V, Hillmann K, Kottner J, et al. Effect of minoxidil topical foam on frontotemporal and vertex androgenetic alopecia in men: a 104-week open-label clinical trial. J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1183-9. Resumo

38. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. Resumo

39. Lee S, Lee YB, Choe SJ, et al. Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Derm Venereol. 2019 Jan 1;99(1):12-17.Texto completo  Resumo

40. Nguyen DD, Marchese M, Cone EB, et al. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol. 2021 Jan 1;157(1):35-42.Texto completo  Resumo

41. Blume-Peytavi U, Hillmann K, Dietz E, et al. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011 Dec;65(6):1126-1134.e2. Resumo

42. Lucky AW, Piacquadio DJ, Ditre CM, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004 Apr;50(4):541-53. Resumo

43. Yeon JH, Jung JY, Choi JW, et al. 5 mg/day finasteride treatment for normoandrogenic Asian women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):211-4. Resumo

44. Oliveira-Soares R, E Silva JM, Correia MP, et al. Finasteride 5 mg/day Treatment of Patterned Hair Loss in Normo-androgenetic Postmenopausal Women. Int J Trichology. 2013 Jan;5(1):22-5.Texto completo  Resumo

45. Price VH, Roberts JL, Hordinsky M, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol. 2000 Nov;43(5 pt 1):768-76. Resumo

46. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005 Mar;152(3):466-73. Resumo

47. Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: a retrospective review of 316 patients. J Am Acad Dermatol. 2020 Nov;83(5):1478-9. Resumo

48. Fernandez-Nieto D, Saceda-Corralo D, Jimenez-Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss. J Am Acad Dermatol. 2020 Nov;83(5):e355-6. Resumo

49. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63(5):463-92. Resumo

50. Sadick NS, White MP. Basic hair transplantation: 2007. Dermatol Ther. 2007 Nov-Dec;20(6):436-47. Resumo

51. Lueangarun S, Panchaprateep R, et al. J Am Acad Dermatol. May 2015; Volume 72, Issue 5, Supplement 1, Page AB113

52. Chan L, Cook DK. Female pattern hair loss. Aust J Gen Pract. 2018 Jul;47(7):459-464.Texto completo  Resumo

53. Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006 Dec;55(6):1014-23.Texto completo  Resumo

54. Gubelin Harcha W, Barboza Martínez J, Tsai TF, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar;70(3):489-98.e3. Resumo

55. Kim H, Choi JW, Kim JY, et al. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatol Surg. 2013 Aug;39(8):1177-83. Resumo

56. Lanzafame RJ, Blanche RR, Bodian AB, et al. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers Surg Med. 2013 Oct;45(8):487-95. Resumo

57. Chen JX, Justicz N, Lee LN. Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review. Facial Plast Surg. 2018 Dec;34(6):631-640.Texto completo  Resumo

58. Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999 Oct;41(4):550-4. Resumo

59. Plante J, Robinson I, Elston D. The need for potassium monitoring in women on spironolactone for dermatologic conditions. J Am Acad Dermatol. 2022 Nov;87(5):1097-9. Resumo

60. Plovanich M, Weng QY, Mostaghimi A. Low usefulness of potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015 Sep;151(9):941-4.Texto completo  Resumo

61. Lee KS, Zhang JJY, Kirollos R, et al. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas. Sci Rep. 2022 Feb 4;12(1):1942.Texto completo  Resumo

62. Medicines and Healthcare products Regulatory Agency. ​Cyproterone acetate: new advice to minimise risk of meningioma. Jun 2020 [internet publication].Texto completo